Founders ask us this question every week: "How do we use content to attract investors?" The honest answer is uncomfortable. You don't attract investors with content. You attract them with recognition — and content is the cheapest, most scalable way to engineer recognition before you ever open a round.
This piece is about the actual mechanics. Not "post on LinkedIn more." The specific, repeatable tactics we've seen work for funded biotech and life sciences startups in 2025-2026.
The investor decision tree (most founders don't see)
When a biotech VC encounters a new company, three things happen in this order:
- Pattern recognition. "Have I heard of this founder? This category? This approach?"
- Social proof scan. "Who's already endorsing this? Who's commenting? Who's quoting them?"
- Substance check. "Now that I'm interested — does the science actually hold up?"
Most founders pour all their energy into step 3. They have stunning data, beautiful pitch decks, defensible IP. But they lose at step 1. By the time the partner reads the deck, they've already decided whether you're "credible-feeling" or "another applicant."
Tactic 1: The pre-fundraise authority window
Six months before you plan to open a round, begin a deliberate visibility campaign. Not a "we're fundraising" announcement (please don't). Instead: a series of substantive contributions to your category's conversation. Op-eds. LinkedIn perspective pieces. Conference talks. Podcast appearances.
The goal is simple: when an investor encounters your name, it's the third or fourth time — not the first. Familiarity converts.
What "substantive" actually means
Not promotional. Not vague. Specific arguments about specific things in your field that take a defensible position. Investors are pattern-matchers; they're trained to spot fluff. The moment you sound like a brochure, you've lost the recognition you were trying to build.
Tactic 2: Engineer your "second-degree" graph
VCs trust their network more than they trust your deck. When they ask another founder, KOL, or operator about you — the answer they get determines your fate.
This means your visibility strategy needs to reach the people who reach investors. Not just investors directly. Translate this to:
- Comment substantively on posts by recognized KOLs in your space
- Co-create content with respected scientists, even informally
- Be useful to other founders publicly — investors notice generosity
- Build relationships with journalists at Endpoints, Fierce Biotech, BioSpace
The fastest path to investor recognition is rarely directly to investors. It's through the trusted intermediaries they already listen to.
Tactic 3: Make your work findable in AI search
This is the 2026 version of "be on Google." A growing percentage of biotech VC research now begins inside ChatGPT, Perplexity, or Google AI Overviews. If those models don't surface you when an investor asks "who's working on [your category]?" — you're invisible to a fast-growing slice of the funnel.
This requires deliberate work: structured data, llm.txt files, content formatted for AI extraction, brand entity engineering. Most biotechs do none of this. The early movers will own the citations for years.
Tactic 4: The "warm cold email" that works
Even the best content strategy benefits from direct outreach. But the email that converts isn't the cold pitch. It's the one that arrives after the investor has already encountered your name three times. The opening line writes itself: "I noticed you commented on [piece] — wanted to share what we're building, since I think it solves the problem you raised."
Now you're not a stranger. You're a familiar voice with a relevant point of view. That email gets a response.
The honest timeline
This is not a 30-day strategy. Sustainable investor visibility takes 6-9 months of compounding work. The biotechs that start when they need to fundraise are too late. The ones that start a year before they think they'll fundraise — they're the ones whose rounds get oversubscribed.
Begin now. Even if your next round feels far away. Especially if it does.